A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants

The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults.
CD can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. CD is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role.
The usual treatment for CD includes injecting BoNT into the affected muscles, but the treatment only lasts about 3 months. IPN10200 is designed to last for a longer period.
The study will consist of two periods:
1. A Screening Period of up to 4 weeks (28 days) to assess whether a participant can take part in the study and requires at least one visit.
2. A Treatment Period of 36 weeks.
On Day 1 of the treatment period, participants will receive either IPN10200 Dose A or Dose B (additional participants may receive IPN10200 Dose C) of the study drug, or placebo distributed into different muscles in the head, neck and shoulders. Participants may continue some other medications, but details need to be recorded.
There will be 10 visits to the clinic in person and one remote visits (phone call) (12 visits to the clinic for participants who receive Dose C). Participants will undergo blood samplings, urine collections, physical/neurological examinations, and clinical evaluations. Participants will also need to complete questionnaires throughout the study.
The total study duration for a participant will be up to 40 weeks (approximately 9 months).

开始日期2025-04-30

申办/合作机构

Ipsen SA

IRCT20101012004920N11

/ Suspended临床3期

Comparison the efficacy and safety of botulinum toxin type A of Plasma Darman Sarve Sepid Company with Dysport® of Ipsen Co. in the treatment of the moderate to severe glabellar lines: a randomized, active controlled, double-blind, non-inferiority phase 3 trial

开始日期2025-04-21

申办/合作机构-

IRCT20200731048257N3

/ Recruiting临床1期

safety and effectiveness of Biosimilar Abobotulinum toxin type A in the treatment of moderate to severe frown lines, A phase I Clinical trials study

开始日期2024-10-31

申办/合作机构-

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的临床结果

登录后查看更多信息

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的转化医学

登录后查看更多信息

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的专利（医药）

登录后查看更多信息

1,127

项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的文献（医药）

2025-07-01·CLINICAL NEUROLOGY AND NEUROSURGERY

The use of onabotulinum toxin type A and other neurotoxins for the treatment of chronic migraine: An American Headache Society survey study

Article

作者: Hamilton, Kendra ; Mathew, Paul G ; Ali, Ashhar ; Agarwal, Utkarsh

PURPOSE:

OnabotA is the only US Food and Drug Administration-approved neurotoxin for chronic migraine prevention; however, non-onabotA toxins may be equally effective. Few studies have explored clinician practices and patient outcomes with non-onabotA neurotoxins. Our study aimed to generate a statistical snapshot of clinician perspectives and treatment practices regarding onabotulinum toxin A (onabotA) and other neurotoxins for chronic migraine and comorbid conditions.

METHODS:

A 15-question survey was distributed online to clinician members of the American Headache Society (AHS) assessing clinical practices using onabotA and non-onabotA toxins for chronic migraine and comorbid conditions, and descriptive analysis was performed.

RESULTS:

168 respondents (162 from the United States and 6 from Canada) completed the survey (response rate 10.1 % [168/1665]). Of 48 respondents (28 % of total) using non-onabotA toxins for chronic migraine, 27 (16 %) used incobotulinum toxin A; 23 (14 %) used abobotulinum toxin A; and 12 (7 %) used rimabotulinum toxin B. Non-onabotA toxins were predominantly used due to administration/payor imposed issues (19/48; 40 %) and cost (18/48 [38 %]). Most clinicians using non-onabotA toxins reported similar efficacy to onabotA (32/48; 67 %), while fewer reported better efficacy (9/48 [19 %]) or worse efficacy (7/48 [15 %]) than onabotA. Many respondents (114/168 [68 %]) had used neurotoxins for chronic migraine in addition to other comorbid conditions, including temporomandibular joint disorders (95/114 [83 %]) and cervical dystonia (64/114 [56 %]).

CONCLUSION:

While non-onabotA toxins are used less frequently for chronic migraine, they may have similar efficacy as onabotA and are used off-label in clinical practice due to administrative/payor issues or cost.

2025-05-12·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Impact of botulinum therapy on long-term control of cervical dystonia symptoms and patient satisfaction with treatment: results of the international prospective observational study INTEREST IN CD2 in Russian subgroup of patients

Article

作者: Maisonobe, P. ; Pokhabov, D.B. ; Korenko, A.N. ; Khasanova, D.R. ; Grigoryan, A.A. ; Baikova, A.N. ; Karpova, M.I.

Objective. To evaluate effect of long-term BTA treatment on cervical dystonia (CD) symptoms control and patient satisfaction with botulinum therapy in real life setting. Material and methods. A total of 1050 patients took part in the international observational study INTEREST IN CD2, the analysis included data from 995 patients (overall population), of which 56 patients were enrolled In Russia. CD clinical assessment was performed at baseline and on the days of BTA injections using the TWSTRS scale and tremor component of the Tsui scale. Patient satisfaction with CD symptoms control was evaluated using 5-point Likert scale on the day of the visit (today satisfaction) and the highest level of satisfaction at any time since the last BTA injection (highest satisfaction). This article presents the results of the analysis of the Russian subgroup of patients in comparison with the overall study population. Results. In 5 Russian investigational sites, 44 (78.6%) women and 12 (21.4%) men were enrolled in the study; the patients’ mean age was 51.1±9.6 years, the mean duration of the disease was 7.3±5.6 years. The baseline characteristics of the Russian patients were comparable to the overall population, but severity of CD symptoms was numerically higher in the Russian subgroup: the mean TWSTRS severity scores were 17.4±5.0 and 15.9±5.7, respectively; segmental dystonia was observed more frequently (14.3% and 7.4% of patients), as well as shoulder elevation (73.2% and 50.5%) and jerk (21.4% and 9.6%). The vast majority of Russian patients (82.1%) received treatment with abobotulinumtoxin (Dysport). In the Russian subgroup, higher doses of Dysport (median doses 800.0 U and 500.0 U), larger number of targeted muscles (4.3±1.5 and 3.5±1.5) and injection points (11.7±5.5 and 8.1±5.0) were used compared to the overall population. In the Russian subgroup, the mean TWSTRS total score (assessed at the end of each injection cycle) decreased from 32.3±11.2 to 25.2±15.7 over the 3 years follow-up; there was also decrease in severity score from 17.4±5.0 to 12.6±7.5 and disability score from 9.8±4.0 to 7.4±4.8, comparable to the overall population. Patients’ satisfaction with CD symptoms control at peak of the BTA injection effect increased from 92.5% to 98.1% and was higher than in the overall population. At the end of the treatment cycle, patients’ satisfaction was consistently lower than at peak effect. Conclusion. The results of the Russian subgroup analysis showed a high level of long-term effectiveness of botulinum therapy in controlling CD symptoms and patients’ satisfaction with treatment in real clinical practice. Dysport is the most frequently used BTA preparation In Russia, the optimal level of effectiveness with repeated injections of Dysport remains stable and is maintained within the framework of real-life practice, which supports the clinical guidelines recommendations of its use as the drug of choice in the treatment of patients with CD.

2025-05-01·TOXICON

Modelling long-term outcomes in patients with post-stroke spasticity with or without BoNT-A treatment on all-cause mortality and secondary cardiovascular events

Article

作者: Magalhães, Bárbara ; Robbins, Sean ; Nechiporenko, Dmitry ; Whalen, John ; Burchakova, Mariya ; Zaffalon, Andrea ; Balcaitiene, Jovita ; Fheodoroff, Klemens ; Danchenko, Natalya ; Szulc, Elzbieta

App. 25% of stroke survivors develop post-stroke spasticity (PSS) over the first year after a stroke, and they also experience motor weakness, which may prevent effective recovery by restricting mobility and participating in exercise programmes. Patients generally experience rapid improvement with Botulinum Toxin Type A (BoNT-A) therapy for PSS. Unfortunately, clinical trials demonstrating benefits from BoNT-A treatment are of short duration. Consequently, it is not known if treatment-related improvements in mobility could also contribute to lowering the risks of secondary cardiovascular (CV) events and all-cause death. To assess if BoNT-A injections could also have an impact on long-term outcomes, we developed a 10-year survival model comparing the effects of AbobotulinumtoxinA (aboBoNT-A) injections and rehabilitation therapy (aboBoNT-A+RT) with rehabilitation therapy (RT) alone. The Functional Independence Measure (FIM) appeared to be the only functional outcome allowing us to model the effect of aboBoNT-A injections on all-cause mortality. Stroke survivors who reported better improvement in FIM score during rehabilitation had lower risk of all-cause mortality during follow-up. Patients treated with aboBoNT-A injections + RT showed better improvement in FIM score than patients treated without aboBoNT-A injections. Our modelling results showed that the addition of aboBoNT-A injections to RT led to a reduction of 8.8% in the risk of all-cause mortality, and a relative increase of 12.8% in discounted life-years. The addition of aboBoNT-A injections to RT led to an increase in total costs of £42.328 over 10 years (based on National Health Service (NHS) UK cost collection 2018/2019). In the base-case scenario, incremental costs were driven by the increased number of hours of home care and RT for patients treated with aboBoNT-A injections compared with RT alone. Assuming an incremental cost-effectiveness ratio (ICER) threshold of £30.000, the probabilistic sensitivity analysis found a 73% likelihood that aboBoNT-A+RT demonstrated cost-effectiveness compared with RT alone. Our work advocates for the need to consider and to capture the impact of BoNT-A injections on all-cause mortality and secondary events, such as CV events and recurrent stroke, which are prevalent in stroke survivors.

项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的新闻（医药）

2025-05-21

·药事纵横

23andMe 陨落，再生元 2.56 亿美元“抄底”

5月19日，生物制药巨头再生元（Regeneron Pharmaceuticals）宣布以2.56亿美元收购基因检测鼻祖23andMe，当日，23andMe股价盘前暴涨，而再生元股价则相对平稳。23andMe的故事始于2006年，创始人安妮·沃西基（Anne Wojcicki）凭借“唾液测基因”的创新模式，将消费级基因检测推向大众。通过祖源分析和健康风险评估，公司迅速积累1500万用户，市值一度飙升至60亿美元，成为硅谷明星企业。但这种商业模式的核心矛盾逐渐暴露：消费级基因检测并非刚需。用户多为一次性购买，复购率极低，而低价策略虽扩大了市场，却难以覆盖高昂的测序和数据处理成本，2024财年累计亏损23亿美元。 2023年的数据泄露事件，真正击垮了23andMe。黑客利用用户旧密码漏洞，窃取近700万客户的基因数据，包括家族关系、健康信息甚至出生年份。这不仅导致3000万美元的和解金，更让用户信任彻底崩塌。此后，公司裁员40%、关闭药物研发部门，最终于2025年3月申请破产保护，市值缩水至不足1亿美元。在这个节骨眼上，再生元瞄准了23andMe 1500万用户的基因数据库。再生元打的什么算盘？再生元以2.56亿美元“抄底”收购23andMe，要知道，23andMe巅峰时期估值60亿美元，如今仅以4%的价格收入囊中，且可选择性剥离亏损业务。近年来，再生元加速布局基因治疗，其VelociSuite平台依赖精准的基因靶点发现，而23andMe的海量数据能极大加速药物研发管线。此外，再生元此前收购的多家基因技术公司，如眼科递送技术公司Oxular、听力治疗公司Decibel均缺乏直接触达消费者的入口，23andMe的C端网络恰好填补这一空白。利用用户健康数据筛选临床试验受试者，或通过祖源分析定位特定疾病高发人群，实现个性化医疗的商业化落地。但是数据整合的难度不容小觑，消费级基因检测的数据质量与医学研究标准存在鸿沟：23andMe的祖源报告基于单核苷酸多态性（SNP）芯片，仅覆盖基因组中0.1%的位点，而药物研发需全基因组测序的深度数据。再生元能否将数据优化并准确应用，仍是未知数。尽管再生元承诺遵守隐私政策并接受法院监督，但毕竟有一次前车之鉴，可想而知公众对此仍然不够放心。23andMe的数据泄露阴影尚未消散，而基因数据的特殊性使其一旦泄露后果远超普通个人信息，因为它无法更改，且关联整个家族。况且，美国联邦法律对基因数据的保护极为有限：《健康保险可携性和责任法案》（HIPAA）仅适用于医疗机构，而《基因信息反歧视法》仅限制雇主和保险公司的歧视行为。即便加州等11个州赋予用户删除数据的权利，但再生元作为制药巨头，完全可能通过数据匿名化或研究合作绕过限制。伦理边界同样是一个难题，23andMe曾将匿名化数据授权给葛兰素史克（GSK）用于药物研发，用户虽签署同意书，但多数人并未意识到自己的基因可能成为药企的“原料”。再生元的收购加剧了这种疑虑：若数据用于开发天价罕见病药物，用户能否分享收益？若算法基于数据偏见导致医疗歧视，谁该负责？这些问题尚无明确答案，加州司法部长罗伯·邦塔（Rob Bonta）已发表紧急呼吁，要求用户立即删除数据。23andMe的失败暴露了消费级基因检测的商业化困局，但其数据的医疗价值仍不可否认，遗传病筛查、肿瘤基因检测、传染病诊断等更具刚需的领域成为新热点。再生元的收购或许预示着一种新模式：药企通过收购数据入口，直接打通研发与市场。早先，诺华、罗氏等巨头自建基因数据库；Ancestry、Color Health等公司则聚焦健康风险评估与临床结合。再生元的差异在于其试图将消费数据与药物开发深度绑定，例如利用人群基因多样性优化临床试验设计，或通过大数据预测药物副作用。若成功，这将彻底改变传统药企高投入、低产出的研发模式。但风险同样显著。23andMe的案例证明，数据驱动的商业模式极度依赖公众信任。再生元若无法解决隐私争议，可能重蹈覆辙。此外，消费基因检测与制药研发的文化差异也可能导致整合失败，前者追求用户增长与市场声量，后者注重科学严谨与合规性。对再生元而言，2.56亿美元的代价或许低廉，但如何将数据转化为真正的临床突破，如何平衡商业利益与用户权益，才是真正的试金石。参考来源：[1]Regeneron to Buy 23andMe for $256 Million in Bankruptcy Auction, by Haseeb Qureshi, Endpts, 2025-05-20[2]Pharmaceutical Company Regeneron Acquires Genetics Testing Firm 23andMe for $256 Million, by Benzinga, 2025-05-19[3]Regeneron to Acquire 23andMe for $256 Million, by Yahoo Finance, 2025-05-19药事纵横投稿须知：稿费已上调，欢迎投稿

并购基因疗法

2025-02-10

·PRNewswire

Connecticut Pain Solutions Offers Innovative Platelet-Rich Plasma (PRP) Treatments

WALLINGFORD, Conn., Feb. 10, 2025 /PRNewswire/ -- Connecticut Pain Solutions is excited to announce the availability of its cutting-edge Platelet-Rich Plasma (PRP) treatments. These advanced treatments are designed to address a range of conditions, offering patients a minimally invasive way to accelerate healing and improve their quality of life. Continue Reading Connecticut Pain Solutions is dedicated to providing exceptional care for those dealing with neurological conditions and chronic pain. The practice's mission is to combine state-of-the-art technology with compassionate, patient-centered care to deliver innovative solutions that improve lives. Our goal is always to stay ahead of the curve and provide our patients with the most cutting-edge solutions. Post this Led by Dr. Igor Turok, a board-certified and award-winning physician, the practice is at the forefront of advancements in neurological and pain treatments. Dr. Turok brings a wealth of knowledge and decades of experience, holding memberships in prestigious organizations such as the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Neurology and Psychiatry, the International Spine Intervention Society, and the American Society of Anesthesiologists. Dr. Turok has also earned recognition for his expertise in combining ultrasonography, electroencephalography, electromyography, and nystagmography in his treatment approaches. His innovative use of tools such as Magellan and Eclipse PRP® platelet-rich plasma centrifuges, Botox® and Dysport® for therapeutic purposes, and the Pro-Nox™ Nitrous Oxide System further emphasizes the practice's commitment to offering the most advanced care available. "We are thrilled to offer PRP therapy to our patients," said Dr. Igor Turok. "This innovative treatment opens up new possibilities for pain management and healing, using the body's natural abilities to restore and rejuvenate. Our goal is always to stay ahead of the curve and provide our patients with the most effective and cutting-edge solutions." Connecticut Pain Solutions offers the following services to address a wide range of needs and conditions: Advanced neurological diagnostics (EEG, EMG, and more) Pain management treatments (Botox®, PRP therapy, and more) Customized care for chronic conditions, including migraines and neuropathy Rehabilitation and recovery support About Connecticut Pain Solutions Connecticut Pain Solutions is a trusted name in neurological care and pain management, serving the Ridgefield and Wallingford communities. The practice takes pride in offering innovative treatments that prioritize patient well-being and long-term outcomes. Contact the team at Connecticut Pain Solutions to schedule an appointment or learn more about how PRP therapy and other treatments could improve lives. Wallingford Location: 101 N Plains Industrial Rd, Suite 100 Wallingford, CT 06492 Phone: (203) 626-9080 Ridgefield Location: 38B Grove St, Suite 203 Ridgefield, CT 06877 Phone: (475) 215-5660 Visit to learn more about the practice and its innovative offerings. SOURCE Connecticut Pain Solutions WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-23

·GlobeNewswire-Health Care

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. YTD 2024 YTD 2023 % change Q3 2024 Q3 2023 % change €m €m Actual CER1 €m €m Actual CER1 Oncology 1 829,8 1 744,1 4,9% 5,8% 604,0 574,5 5,1% 5,6% Neuroscience 536,4 489,0 9,7% 11,8% 181,9 164,8 10,4% 10,1% Rare Disease 129,7 76,0 70,7% 71,3% 50,8 33,2 53,1% 54,4% Total Sales 2 495,9 2 309,1 8,1% 9,2% 836,6 772,4 8,3% 8,6% Highlights Total-sales growth in the year to date of 9.2% at CER1, or 8.1% as reported, with notable performances from Dysport® (abobotulinumtoxinA), Cabometyx® (cabozantinib) and Bylvay® (odevixibat), with robust Somatuline® (lanreotide) sales, as well as the increasing contribution from the launches of Iqirvo® (elafibranor) in 2L PBC2 and Onivyde® (irinotecan) in 1L mPDAC3 Regulatory approvals in the E.U. of Iqirvo and Kayfanda® (odevixibat)Increased 2024 financial guidance: total-sales growth greater than 8.0% at CER1 (prior guidance: greater than 7.0% at CER1); core operating margin greater than 31.0% of total sales (prior guidance: greater than 30.0%) “Since the launch of our strategy in 2020, we have enjoyed uninterrupted growth. This quarter was no exception and was accompanied by further progress in the pipeline”, commented David Loew, Chief Executive Officer. “We have also continued to launch across several indications and lines of therapy, including the recent rollouts of Iqirvo and Onivyde, which are progressing well. Supported by the performance so far this year, we are further increasing our 2024 sales and margin guidance.” “We have built a track record of delivery, grounded in a strong foundation of external innovation, commercial excellence and our ongoing mission to offer more choices for patients.” Full-year 2024 guidance Based on the strong performance in the third quarter, Ipsen has further increased its financial guidance for 2024: Total-sales growth greater than 8.0%, at constant currency (prior guidance of greater than 7.0%). Based on the average level of exchange rates in September 2024, an adverse impact on total sales of around 1.5% from currencies is expectedCore operating margin greater than 31.0% of total sales (prior guidance of greater than 30.0%) Pipeline update In September 2024, the European Commission conditionally approved Iqirvo 80mg tablets for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a monotherapy in patients unable to tolerate UDCA. Iqirvo was approved in the same setting by the U.S. FDA in June 2024. In September 2024, the European Commission also approved Kayfanda as a treatment for pruritus in children from as young as six months of age who have Alagille syndrome (ALGS). Odevixibat, under the brand name Bylvay, is already marketed in the E.U. for the treatment of progressive familial intrahepatic cholestasis (PFIC), and in the U.S. and E.U. for PFIC, and in the U.S. for ALGS. In the same month, final results from the CABINET Phase III trial were presented at the 2024 European Society for Medical Oncology Congress and were published in the New England Journal of Medicine, reinforcing the efficacy benefits of Cabometyx in advanced neuroendocrine tumors. It was announced at that time that Ipsen had submitted an extension of indication Marketing Authorization to the European Medicines Agency. Business development In August 2024, Ipsen entered into an agreement to sell its rare pediatric disease Priority Review Voucher. As part of the agreement, Ipsen received a cash payment of $158m in the third quarter. In October 2024, Eton Pharmaceuticals entered into an agreement with Ipsen to acquire Increlex® (mecasermin injection). The transaction is expected to close before the end of 2024. Arbitration proceedings with Galderma As of 30 September 2024, two arbitration proceedings initiated by Galderma against Ipsen at the International Chamber of Commerce (ICC) were ongoing. The first dispute, initiated by Galderma in 2021, pertains to the territorial scope of the commercial partnership related to Azzalure® (abobotulinumtoxinA) and Dysport under an agreement signed in 2007 in the E.U., in certain Eastern European countries, and in Central Asia. The Tribunal of the ICC Internal Court of Arbitration issued a final award, in October 2024, dismissing most, if not all, of Galderma's claims in this first arbitration and ordered that Galderma bear the majority of the legal fees and arbitration costs incurred by Ipsen. A second dispute was initiated by Galderma in November 2023, related to the validity of Ipsen’s 2023 termination of a joint R&D collaboration agreement entered into in 2014 under the parties’ respective early-stage neurotoxin programs, including the development of IPN10200. At this stage, Ipsen cannot reasonably predict any potential financial impact from this final remaining arbitration process, for which it intends to fully defend and vindicate its rights. Conference call A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here; webcast details can be found here. Calendar Ipsen intends to publish its full-year and fourth-quarter results on 13 February 2025. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the nine-month period to 30 September 2024 (YTD 2024) and the three-month period to 30 September 2024 (Q3 2024), compared to the nine-month period to 30 September 2023 (YTD 2023) and the three-month period to 30 September 2023 (Q3 2023), respectively. Commentary is based on the performance in YTD 2024, unless stated otherwise. About Ipsen Ipsen is a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fuelled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. Ipsen contacts Investors Craig Marks +44 (0)7584 349 193 Nicolas Bogler +33 6 52 19 98 92 Media Jennifer Smith-Parker +44 (0) 7843 137 764Anne Liontas +33 7 67 34 72 96 1 At constant exchange rates (CER), which excludes any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.2 Second-line primary biliary cholangitis.3 First-line metastatic pancreatic ductal adenocarcinoma. Attachment Ipsen - YTD 2024 sales announcement

上市批准临床3期临床结果引进/卖出

100 项与 A型肉毒杆菌毒素（Ipsen Biopharm Ltd）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09764	A型肉毒杆菌毒素（Ipsen Biopharm Ltd）	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
面部皮肤病	中国	Ipsen Developments Ltd.	2020-06-17
肌肉痉挛	美国	Ipsen Biopharm Ltd.	2017-06-14
上下肢痉挛	美国	Ipsen Biopharm Ltd.	2016-07-29
眉间纹	美国	Ipsen Biopharm Ltd.	2009-04-29
斜颈	美国	Ipsen Biopharm Ltd.	2009-04-29
肌张力失调	奥地利	Ipsen SA	2009-01-28
肌张力失调	比利时	Ipsen SA	2009-01-28
肌张力失调	保加利亚	Ipsen SA	2009-01-28
肌张力失调	克罗地亚	Ipsen SA	2009-01-28
肌张力失调	塞浦路斯	Ipsen SA	2009-01-28
肌张力失调	捷克	Ipsen SA	2009-01-28
肌张力失调	丹麦	Ipsen SA	2009-01-28
肌张力失调	爱沙尼亚	Ipsen SA	2009-01-28
肌张力失调	芬兰	Ipsen SA	2009-01-28
肌张力失调	法国	Ipsen SA	2009-01-28
肌张力失调	德国	Ipsen SA	2009-01-28
肌张力失调	希腊	Ipsen SA	2009-01-28
肌张力失调	匈牙利	Ipsen SA	2009-01-28
肌张力失调	冰岛	Ipsen SA	2009-01-28
肌张力失调	爱尔兰	Ipsen SA	2009-01-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
偏头痛	临床3期	美国	Ipsen SA	2023-09-29
偏头痛	临床3期	加拿大	Ipsen SA	2023-09-29
偏头痛	临床3期	捷克	Ipsen SA	2023-09-29
偏头痛	临床3期	法国	Ipsen SA	2023-09-29
偏头痛	临床3期	格鲁吉亚	Ipsen SA	2023-09-29
偏头痛	临床3期	德国	Ipsen SA	2023-09-29
偏头痛	临床3期	波兰	Ipsen SA	2023-09-29
偏头痛	临床3期	西班牙	Ipsen SA	2023-09-29
下肢痉挛	临床3期	美国	Ipsen SA	2018-05-01
多发性硬化症	临床3期	美国	Ipsen SA	2016-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05167864 (JBDX, CTgov)	N/A	-	143	Onabotulinumtoxina for Injection (OnabotulinumtoxinA)	顧築觸夢觸願齋顧積鹽(衊觸鏇遞廠鏇鏇製鹹齋) = 醖鏇選淵憲餘範製觸鹹觸鹹糧願艱膚齋衊遞鏇 (鹽鏇壓廠遞齋遞夢簾範, 5.0) 更多	-	2025-01-17
				Abobotulinumtoxina for Injection (AbobotulinumtoxinA)	顧築觸夢觸願齋顧積鹽(衊觸鏇遞廠鏇鏇製鹹齋) = 願觸製醖獵壓衊艱築觸觸鹹糧願艱膚齋衊遞鏇 (鹽鏇壓廠遞齋遞夢簾範, 5.2) 更多
NCT05277337 (STAR, CTgov)	临床4期	眉间纹	150	Alluzience (Group 1 (Alluzience))	廠膚廠鬱觸鬱憲鏇夢憲(鬱醖廠網鹽鑰願鬱鑰願) = 簾壓襯遞壓積衊鑰獵鏇願鬱襯網夢鏇鬱積鹹鑰 (淵繭蓋積範製鹽鏇壓構, 0.414) 更多	-	2024-02-16
				BoNT-A+Vistabel (Group 2 (Powder BoNT-A: BOTOX/Vistabel))	廠膚廠鬱觸鬱憲鏇夢憲(鬱醖廠網鹽鑰願鬱鑰願) = 窪鹹鹹膚網鑰壓願顧憲願鬱襯網夢鏇鬱積鹹鑰 (淵繭蓋積範製鹽鏇壓構, 0.831) 更多
NCT03543254 (CTgov)	临床2期	偏头痛 \| 慢性病	20	BoNT-A	網願範觸淵製壓壓餘齋 = 鹹選壓鹹構憲廠鏇夢網範鏇觸鹽鑰簾簾選鏇廠 (鏇醖選鑰鏇衊憲膚醖顧, 繭衊鹽製構鏇積襯構廠 ~ 窪鹹積鏇壓廠顧艱夢餘) 更多	-	2024-01-30
MDS2022	N/A	颈肌张力障碍	27	Dysport	鏇膚衊衊觸積糧繭鹽夢(憲壓醖築鹹選醖醖鬱壓) = 鏇鏇構艱蓋醖糧齋廠壓廠繭願淵願繭鏇夢製願 (獵鏇構觸壓襯憲壓齋糧 ) 更多	积极	2022-09-15
				Botox/Xeomin	築窪築憲衊艱製簾窪顧(遞鬱鬱鹽鑰觸艱憲膚構) = 鹽鏇積憲艱遞餘淵繭製衊製顧壓鬱選齋築鏇鏇 (蓋襯願憲蓋願鑰築網餘 )
NCT03469999 (CTgov)	临床3期	脑瘫	12	Dysport	糧築築壓繭醖獵壓廠簾(鹽鏇夢鬱餘餘齋壓築鹹) = 觸齋觸網齋遞鬱鬱觸衊壓顧憲醖夢糧衊簾淵觸 (繭觸構遞簾廠顧觸構夢, 簾鏇鹽鹽廠膚廠蓋夢壓 ~ 襯製獵蓋觸艱糧衊蓋膚) 更多	-	2022-06-01
NCT01459666 (CTgov)	临床4期	瘢痕 \| 额头皱纹 \| 皮肤肿瘤 ... 更多	9	Dysport (Dysport (abobotulinumtoxinA))	觸蓋夢製淵淵膚艱鏇窪(鏇淵鹹憲積遞觸遞選餘) = 壓繭顧醖憲糧製醖艱獵憲鏇簾範願構廠觸鏇築 (憲構窪糧糧鑰衊願衊鹹, 觸艱顧獵鹽製繭廠範蓋 ~ 醖鑰繭築築膚鹽遞鹹餘) 更多	-	2022-05-26
				Bacteriostatic 0.9% Sodium Chloride (vehicle) (Placebo)	觸蓋夢製淵淵膚艱鏇窪(鏇淵鹹憲積遞觸遞選餘) = 製憲鹽膚遞糧餘築積簾憲鏇簾範願構廠觸鏇築 (憲構窪糧糧鑰衊願衊鹹, 壓醖膚蓋選鏇餘蓋獵襯 ~ 膚憲膚觸鹹製鑰壓壓憲) 更多
NCT02660138 (CONTENT1, CTgov)	临床3期	尿失禁 \| 神经源性逼尿肌过度活动 \| 脊髓损伤 ... 更多	227	placebo (Placebo)	艱襯鑰獵窪顧顧鑰選蓋(夢簾襯廠遞築簾鹹壓鹽) = 構醖鹹壓壓窪糧艱遞壓淵積網餘齋網壓膚糧製 (獵壓遞餘齋艱網積膚簾, 2.01) 更多	-	2021-06-16
				Dysport (Dysport® 600 U)	艱襯鑰獵窪顧顧鑰選蓋(夢簾襯廠遞築簾鹹壓鹽) = 淵壓窪築膚願範膚廠積淵積網餘齋網壓膚糧製 (獵壓遞餘齋艱網積膚簾, 2.04) 更多
AAN2021	N/A	颈肌张力障碍	-	AbobotulinumtoxinA 500U	顧壓膚鬱淵艱獵壓衊窪(淵鹹選製淵廠餘繭夢網) = 窪構壓願衊醖鏇繭夢鹹簾選鑰夢壓簾簾夢築網 (壓衊淵艱鑰餘醖廠蓋窪, 4.0)	-	2021-04-13
				Placebo	顧壓膚鬱淵艱獵壓衊窪(淵鹹選製淵廠餘繭夢網) = 憲壓鏇窪醖顧積膚廠艱簾選鑰夢壓簾簾夢築網 (壓衊淵艱鑰餘醖廠蓋窪, 4.3)
NCT03736928 (CTgov)	临床2期	眉间纹	401	placebo	窪廠壓網顧醖積艱範窪 = 鹹蓋鏇廠簾廠鏇衊淵蓋鬱衊糧鏇鬱淵構願網衊 (鹽顧簾製顧觸簾構鹽衊, 遞鬱夢壓繭鑰構壓鹽顧 ~ 顧艱廠夢繭餘構構蓋廠) 更多	-	2021-02-11
NCT04080882 (CTgov)	临床2期	-	80	Placebo (Placebo)	窪顧窪鹹餘壓鹽築網網 = 憲遞積壓鬱壓壓鏇範積範獵醖艱蓋膚鏇糧膚選 (簾積壓醖鏇糧願簾鏇夢, 簾鏇鹽鹽憲觸顧齋築夢 ~ 鬱鏇醖膚積夢憲鏇鑰願) 更多	-	2021-01-22
				AbobotulinumtoxinA dose 1 (AbobotulinumtoxinA Dose 1)	窪顧窪鹹餘壓鹽築網網 = 衊鏇壓齋壓蓋襯憲選餘範獵醖艱蓋膚鏇糧膚選 (簾積壓醖鏇糧願簾鏇夢, 獵膚餘齋憲網願蓋遞淵 ~ 鏇膚夢淵選鬱願鬱積蓋) 更多